FDA — authorised 24 December 2008
- Application: NDA022369
- Marketing authorisation holder: ABBVIE
- Local brand name: LATISSE
- Indication: SOLUTION/DROPS — TOPICAL
- Status: approved
🇺🇸 Bimatoprost cutaneous solution 0.03% in United States
FDA authorised Bimatoprost cutaneous solution 0.03% on 24 December 2008
Marketing authorisation
Other Ophthalmology approved in United States
Frequently asked questions
Is Bimatoprost cutaneous solution 0.03% approved in United States?
Yes. FDA authorised it on 24 December 2008.
Who is the marketing authorisation holder for Bimatoprost cutaneous solution 0.03% in United States?
ABBVIE holds the US marketing authorisation.